Introduction
Surgical resection with negative margins is the cornerstone of effective multimodality therapy for most solid malignancies. Surgery for high-grade glial neoplasms is inherently limited by the propensity of these tumors to widely infiltrate the normal brain, making total tumor removal an unrealized ideal [1] . Although postoperative recurrence is universal, glioblastomas (GBMs) exhibit a wide range of clinical behaviors, with many tumors recurring as a well-localized mass in the earlier resection cavity, whereas others present, initially or at recurrence, with extensive white matter, transcallosal, or subependymal spread [2] . The exact molecular mechanisms that underlie glioma cell invasion of the surrounding tissue remain to be elucidated, and as such, little data exist to explain the clinical heterogeneity of GBM, or more specifically, what mechanisms drive the numerous pathoanatomic phenotypes observed in this disease.
Epidermal growth factor (EGF) module-containing mucin-like hormone receptor-3 (EMR-3) is a member of the EGF-7 transmembrane (EGF-TM7) family of proteins. Its ligand and cellular functions are entirely unknown [3] , and most of what is known about this protein comes from functional genomics, which suggest that it is a G-protein coupled receptor [4] . Earlier study has shown its expression localized to mature granulocytes [3, 4] .
We first became interested in EMR-3 while analyzing microarray survival data for GBM on The Cancer Genome Atlas website [5] . A Kaplan-Meier analysis performed using this database on 13 September 2009 showed a significant survival benefit for patients with tumor specimens showing EMR-3 downregulation (P < 0.001) ( Fig. 1 ). Given the known limitations of microarray analysis, these results lead us to further study EMR-3 to clarify whether EMR-3 was actually expressed in GBM, whether this molecule's expression showed interindividual variability, and whether altering the EMR-3 expression in EMR-3 expressing glioma cells caused alterations of cellular function that could be linked to clinical heterogeneity of invasive phenotypes. A score of 0 denoted no positive tumor cells, a score of 1 denoted that 1-5% of the tumor cells stained positive, 2 for 6-25% of the tumor cells, and 3 for more than 25% of the tumor cells.
Methods

Reverse transcription PCR analysis
RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, California, USA) and reverse transcribed using Superscript III kit (Invitrogen, Carlsbad, California, USA) according to the manufacturer's protocol. Gene expression was detected by PCR using Platinum Taq DNA Polymerase High Fidelity (Invitrogen) with the following primers: EMR-3 (5 0 -CTGGC-CTCAC-CTTTA-TGGAA/ GGTGA-AGAGG-TAGGC-CATGA-3 0 ) and HPRT (5 0 -GA CCAG-TCAACA-GGGGAC-AT/CCTGAC-CAAGGAAAGC AA-AG-3 0 ). PCR products were run on a 2% agarose gel in 1Â Tris-acetate-EDTA buffer stained with ethidium bromide and visualized under ultraviolet light. 
ATP chemiluminescence cellular proliferation assay
Proliferation was determined using a previously validated ATP chemiluminescence assay, the ATPlite 1-Step Assay (Perkin Almer, Waltham, Massachusetts, USA) and the experiment was carried out as described previously [6] .
In-vitro cellular migration assay SF767 cells underwent siRNA knockdown with control or EMR-3-targeted transfection for 36 h. 2 Â 10 5 cells were loaded in triplicate into a matrigel invasion chamber (BD Biosciences, San Jose, California, USA) and allowed to migrate toward 10% fetal bovine serum in DMEM for 24 h. Knockdown was verified using western blot. The nonmigratory cells were scraped off and the invading cells were fixed with 4% paraformaldehyde and stained with hematoxylin. Three fields of invading cells were visualized and counted at 20Â for each repetition to determine the invasive index for the two conditions.
Statistical analysis
Between-group comparisons of continuous data were performed using student's t-test. The P value was considered significant below the 5% level (i.e. P < 0.05).
Results
Human glioblastoma cells variably express EMR-3 protein
Immunohistochemistry for EMR-3 on eight primary GBM tissue samples showed robust expression (> 25% of tumor cells) in three of eight, weak expression (1-5% of tumor cells) in one of eight, and no evidence expression in four of eight tissue samples (Fig. 2) . Given the marked differences in EMR-3 expression, these data suggest that the variability in EMR-3 transcripts seen in microarrays might represent real differences at the protein expression level in human patients.
Western blot and reverse transcription PCR showed that EMR-3 is variably expressed in different glioma cell types, and there was a strong correlation between protein and transcript levels. The SF767 cell line showed evidence of high levels of EMR-3 mRNA transcript and protein, whereas U87 showed low levels, and U251 and G55 showed no expression ( Fig. 3) . Given these results, we used the SF767 cell line to further determine the phenotypic impact of EMR-3 expression on GBM cells in vitro.
EMR-3 mediates glioblastoma cell invasion in vitro
EMR-3 is thought to represent an adhesion G-protein coupled receptor, and other members of this family (EGF-TM7) are known to mediate cellular migration and invasion in leukocytes [3, 7] . We used siRNA targeting to knockdown the expression of EMR-3 in the SF767 to determine whether suppression of EMR-3 altered the invasion potential of these cells. As shown in Fig. 4 , knockdown of EMR-3 in SF767 cells had a greater than 3fold reduction in invasion compared with controls (3.42 vs. 1, P < 0.05). These data suggest that EMR-3 is involved in mediating migration and invasion in EMR-3 expressing GBM cells.
EMR-3 does not influence cell proliferation in vitro
We used siRNA to suppress the expression of EMR-3, which we found achieved significant knockdown of the EMR-3 protein for 72 h (Fig. 5 ). The ATP based chemiluminescence assay at 24, 48, and 72 h showed no significant differences in growth rates between control and EMR3 siRNA knockdown (Fig. 5 ). 
Discussion
This study provides the first evidence linking EMR-3 protein expression to cellular behavior in a human disease. More specifically, we found that EMR-3 protein is variably expressed in human GBM tissues and cell lines, and that by suppressing this expression in a high EMR-3 expressing cell line, we could significantly alter the invasive behavior of these cells in an in-vitro assay.
The exact function of EMR-3 is entirely unknown, and no ligands or downstream signaling targets have clearly been linked to EMR-3 [8] , although some evidence suggests that it is involved in cell-cell interactions of activated leukocytes [8] . On the basis of our migration data, combined with the lack of antiproliferative effect of EMR-3 suppression, we hypothesize that EMR-3 is a molecule which is involved in the mediation of cellular transmigration and tissue invasion in normal cells, which in the case of glioma cells might be inappropriately expressed and permit these cells to invade the surrounding tissue. Supporting this hypothesis are observations of the function of other members of the EGF-TM7 family, which seem to be involved in transmigration, and with which EMR-3 shares significant homology. For example, EMR-2 is a member of EGF-TM7 family, which shares significant protein homology with EMR-3, and in fact EMR-3 was first identified as an unintentional coamplification product of an attempt to clone the EMR-2 gene [8] . EMR-2 has been shown to bind chondroitin sulfate glycosaminoglycans, which has been suggested to mediate myeloid lineage cell interaction with the extracellular matrix [9] . Subsequent study showed that EMR-2 is a critical mediator of neutrophil migration, adhesion, and invasion [7, 10] . More pertinent to this study Mustafa and colleagues [11] showed a correlation between tumor cell expression levels of the EGF-TM7 protein CD97 and the presence of metastasis of oral cancers. Thus, when combined with observations regarding the overall function of this family of largely conserved proteins, our data suggests that EMR-3 might mediate invasion functions, which are inappropriately activated in some GBMs.
These observations raise a number of interesting questions, which deserve future investigation. Most notably, the expression of EMR-3 has previously been thought to be restricted to myeloid lineage cells [3] ; however, our 
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Results of the cellular invasion assay in SF767 cells treated with either small interfering RNA (siRNA) targeting EGF module-containing mucinlike hormone receptor-3 (EMR-3) (right bar) or a nontargeted construct (left bar). Invasion index was normalized to the less invasive knockdown (KD) to show fold-decrease in invasiveness by the KD. data suggest that this EMR-3 can be expressed by human cancers. The mechanisms by which oncogenic mutations and alterations in signaling pathways lead the EMR-3 protein to be expressed in cancer cells represent an important question not only for oncology, but also for better understanding EMR-3 function. The downstream effects of EMR-3 are similarly unknown, but likely important. In addition, future in-vivo and clinical efforts will be necessary to further clarify a number of important questions: does EMR-3 protein expression mediate variability in tumor behavior between different GBM patients? Does EMR-3 protein expression predict worsened clinical outcome? Does the loss of EMR-3 in some cell lines explain the lack of infiltrative behavior in some xenograft cell lines? These ambitious questions lie outside the scope of this study.
Conclusion
We provide evidence for the first time the adhesion G-protein coupled receptor EMR-3 is expressed in some human GBMs, and may mediate invasive behavior in these cells. These data serve to identify an interesting potential target for future investigations, and to expand our understanding of EMR-3 function.
